Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
about
Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype scoreNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?Model-based economic evaluations in smoking cessation and their transferability to new contexts: a systematic reviewA review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities.A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.Varenicline for smoking cessation: efficacy, safety, and treatment recommendationsLargely ignored: the impact of the threshold value for a QALY on the importance of a transferability factorSmoking cessation: an economic analysis and review of vareniclineTobacco use and cessation for cancer survivors: an overview for cliniciansCost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessationCost-effectiveness and cost-utility of Internet-based computer tailoring for smoking cessation.Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions.A Qualitative Study of Smoking Behaviors among Newly Released Justice-Involved Men and Women in New York CityThe effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations.Economic evaluation of pharmaco- and behavioral therapies for smoking cessation: a critical and systematic review of empirical research.Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.Pharmacotherapy for smoking cessation: current advances and research topics.Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation.Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models.Are financial incentives cost-effective to support smoking cessation during pregnancy?"Meaningful use" provides a meaningful opportunity.If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands.Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence.Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.An increase in primary care prescriptions of stop-smoking medication as a result of health insurance coverage in the Netherlands: population based study.Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand.
P2860
Q24621065-CEE8297B-A4B2-49C1-A02D-9D31B7C30D5CQ28277165-A8BA77FE-1751-4DFA-88BE-90D4D10C8513Q30496856-B8D357FE-9466-4B50-980B-ECF7D471FC1FQ33697800-D79D8D5D-117A-4926-B98F-95F3A2D1FA9EQ33732066-852DFDF1-A00D-41A5-9D34-A3074CD35A74Q33858665-EE23A1E2-1CF9-40FA-AEB3-E4DF6ABF08E5Q34231551-912D9F16-7CB0-4096-AE40-2F53298E9A95Q35178018-DED6E9A8-563D-4CB9-9A2E-D175D0DB61EBQ35205491-EA0086EA-70FA-42A7-B64A-9D1191F36B55Q35226577-B2E32F43-C561-4ABC-BA42-28CC7FBA3CE7Q36486726-A04B34A3-6E6E-4A3F-AE49-29540BAB1EB5Q36794924-0C38C4AC-5A0F-4A03-AF2B-6D10C8446072Q36871294-D20AB7CE-A015-48F7-A5FB-8073BB18309FQ36954245-9B9D98E9-0B6E-45A0-B17C-928D7BB9B7A2Q37136637-3A96B976-A8E6-412F-BA37-F6033A6ECD9CQ37648843-52357158-75B1-40D0-B610-EC40DCC2EDB3Q37682886-559855C2-F5AF-4D64-BD9B-1F76D7AFFD2FQ37784205-9F508490-64F7-4B46-8F56-3166FA28F238Q37863092-0F0264C6-274B-46B6-9A92-DBB1335172A8Q37976851-79F14C17-C339-4DEC-9B69-E01C4460EF0DQ38010473-9DD74CD1-BA2C-4B58-B357-7A093E2FB958Q41361021-D0E17915-44D1-4F0C-AF7C-956F38AA86C6Q42678465-05CF505C-060D-45C5-A2B1-C7B79EC2692EQ42958013-4F36985B-DDA7-48F8-B89D-18B0EC6B2B10Q43637595-D7B0CC47-F6D6-4C1A-A202-1B9F458FD8E7Q44209085-AA7C6940-872A-4B18-A8C8-035F0514A220Q44667603-F37B19C5-A1A8-4C88-BB2A-636A0654D453Q45288498-DE4AADD3-3E64-4367-AD80-16E25A294CD7Q47967558-5621B474-618E-450B-BAF0-054D5BB8E72D
P2860
Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cost-effectiveness of varenicl ...... cessation in the Netherlands.
@en
type
label
Cost-effectiveness of varenicl ...... cessation in the Netherlands.
@en
prefLabel
Cost-effectiveness of varenicl ...... cessation in the Netherlands.
@en
P2093
P356
P1476
Cost-effectiveness of varenicl ...... cessation in the Netherlands.
@en
P2093
Martine Hoogendoorn
Maureen P M H Rutten-van Mölken
Paco Welsing
P356
10.1185/030079908X242917
P407
P577
2008-01-01T00:00:00Z